Hodgkin Lymphoma Clinical Trials in Toronto, Ontario
9 recruitingToronto, Ontario, Canada
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled399 locationsNCT05675410
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793
Recruiting
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
Classic Hodgkin LymphomaCardiovascular DisorderClonal Hematopoiesis
Children's Oncology Group190 enrolled29 locationsNCT05705531
Recruiting
Phase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-Hodgkin Lymphoma
Canadian Cancer Trials Group30 enrolled8 locationsNCT05998642
Recruiting
Phase 1
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738
Recruiting
Phase 2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Canadian Cancer Trials Group84 enrolled18 locationsNCT05180097
Recruiting
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
OsteosarcomaRecurrent LymphomaLymphoblastic Lymphoma+4 more
Children's Oncology Group420 enrolled79 locationsNCT01790152
Recruiting
Phase 2
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Refractory CancerClassical Hodgkin LymphomaRelapsed Cancer
University Health Network, Toronto37 enrolled1 locationNCT04510636